Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
|Articles|May 20, 2011
Eco-label tags "Environmentalists" systems
In Europe four Shimadzu product series carry the eco-label representing the company's multi-levelled energy saving program. The GCMS-QP2010 Ultra and SE and the LC-20AP systems, as well as the brand-new GC-2025 and the TOC-L series feature the eco-label.
Advertisement
In Europe four Shimadzu product series carry the eco-label representing the company’s multi-levelled energy saving program. The GCMS-QP2010 Ultra and SE and the LC-20AP systems, as well as the brand-new GC-2025 and the TOC-L series feature the eco-label. It tags only the most energy efficient instruments which meet the highest environmental standards. Users profit from lower running and maintenance costs and less energy spending.
The eco-labelled systems save between 25 and 40% energy. Furthermore, materials consumption is lower, operational costs are less and the CO2 emissions have been reduced. More environmentalists systems are already in the production pipeline.
The GCMS-QP2010 Ultra features an eco-mode for stand-by operation allowing a lower total cost of ownership with less environmental stress. The GC-2025’s power consumption is reduced by 30% for programmed temperature analysis in comparison to other GC models. The energy consumption of the TOC-L series has been reduced by 36% (100 V) and 43% (200 V) in comparison with conventional Shimadzu models (assuming 8 hours operation/day × 5 days/week).
For more details please visit
Advertisement
Related to this article
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
Advertisement
Advertisement